Navamedic ASA: Strong growth and important product launch in Q4 2025

Navamedic delivered record Q4 revenue of NOK 157.1m (+19.8% y/y) and full-year revenue of NOK 565.4m (+6.4% y/y), with adjusted EBITDA of NOK 13.4m in Q4 and NOK 47.6m for 2025. Q4 gross margin improved to 40.3% (vs 33.7% prior-year quarter) while full-year margin was 39.0%; growth was driven by the July acquisition of the Addiction portfolio and higher antibiotic sales after 2025 tender wins (Prescription Drugs +24.1% Q4, Hospital +40.3% Q4; full-year Hospital +22.9%). Management flagged a December 2025 launch of Flexilev in OraFID for advanced Parkinson’s (expected modest volumes in 2026) and expects to continue a similar growth path in 2026 while aiming to stabilize gross margins above 40%.

Analysis

Market structure: Navamedic (NAVA) is a direct beneficiary of mid-market hospital tender wins and the Addiction portfolio acquisition: Q4 revenue NOK157.1m (+19.8% y/y) and FY565.4m (+6.4%) show hospital (Hospital +40.3% q/q; +22.9% FY) and antibiotics momentum. Winners include hospital-focused distributors and suppliers to Nordic public tenders; losers are pure-play consumer health OTC names where campaign timing drove -6.6% q/q. The tender-driven revenue implies episodic volume spikes and increased price/volume leverage in hospital channels, improving short-term pricing power if Navamedic sustains >40% gross margin.

Risk assessment: Key tail risks are tender reversals (single-year tender losses can cut hospital revenue >15-25%), integration failure of the Addiction portfolio, and reimbursement/regulatory setbacks for antibiotics or Parkinson’s adjunct therapy (Flexilev in OraFID) that could curtail uptake. Immediate risk (days): knee‑jerk pullback after presentation; short-term (weeks/months): margin stabilization below 40% would invalidate the narrative; long-term (quarters/years): failure to convert modest 2026 Flexilev volume into scale. Hidden dependency: high reliance on tender wins makes free cash flow volatile and multiples sensitive to one-off milestones.

Trade implications: Primary direct play is a tactical long in NAVA sized 2–4% of portfolio with a 6–12 month horizon, targeting 12–25% upside if next two quarters show sequential gross margin >=40% and revenue growth >10% y/y; set hard cut if gross margin <38% or Q1 revenue <NOK135m. Options: buy 6‑9 month call spread (e.g., 15–25% OTM) to cap premium; conservative holders can sell 3‑6 month covered calls to collect premium while retaining upside. Sector rotation: overweight Nordic hospital/pharma distributors, underweight consumer health/OTC exposure until campaign seasonality normalizes.

Contrarian angles: Consensus may underweight execution risk from tender volatility and overvalue the Addiction acquisition as recurring revenue — if Addiction contributes <10% organic growth in 2026, re-rate downside is possible. The market may underprice margin sustainability risk: if Navamedic fails to keep gross margin >40% next two quarters, expect >20% multiple compression. Historical parallels: Nordic mid-cap distributors show cyclic multiples tied to 1–2 large tenders; treat NAVA like a tender-exposed industrial, not a stable pharma royalty name. Unintended consequence: aggressive margin messaging could pressure purchasing behavior in tenders, inviting price competition next cycle.

Key Decisions for Investors

• Establish a 2–4% long position in Navamedic ASA (NAVA) on current levels with a 6–12 month horizon; target total return 12–25% conditional on two consecutive quarters with gross margin >=40% and >10% y/y revenue growth; set stop-loss if gross margin falls below 38% or quarterly revenue <NOK135m.
• Implement a 6–9 month call spread on NAVA (buy 15% OTM call, sell 25% OTM call) sized to equal 1% portfolio exposure to cap premium outlay and capture upside if tender-driven growth continues; roll or close if implied vol >30% or if Q1 guidance disappoints.
• Pair trade: long NAVA (1–2% weight) and short (~1–2% weight) a Nordic consumer-health heavy name or ETF (underweight OTC exposure) to neutralize market beta; prune the short if consumer campaigns reaccelerate (>5% q/q sales uplift announced).
• Reduce broader portfolio exposure to consumer/OTC health stocks by 3–5% in favor of hospital-focused distributors over the next 1–3 months; reallocate freed capital to NAVA and two other Nordic hospital suppliers if NAVA confirms margin stabilization in Q1 2026.